Cefdinir
Cefdinir (Omnicef)
Cefdinir
( SEF-dih-near)
Pregnancy Category: B Omnicef (Rx)

Classification: Cephalosporin, third generation

See Also: See also Cephalosporins.

Action/Kinetics: Maximum plasma levels: 2-4 hr. t 1/2, elimination: 1.7 hr. Excreted through the urine.

Uses: Adults: (1) Community-acquired pneumonia or acute exacerbations of chronic bronchitis due to Haemophilus influenzae (including �-lactamase producing strains), Haemophilus parainfluenzae (including �-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including �-lactamase producing strains). (2) Acute maxillary sinusitis due to Haemophilus influenzae (including �-lactamase producing strains), Streptococcius pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including �-lactamase producing strains). (3) Uncomplicated skin and skin structure infections due to Staphylococcus aureus (including �-lactamase producing strains and Streptococcus pyogenes.)
Children (6 months through 12 years): (1) Acute bacterial otitis media due to H. influenzae (including �-lactamase producing strains), S. pneumoniae (penicillin-susceptible strains only), and M. catarrhalis (including �-lactamase producing strains). (2) Pharyngitis/tonsillitis due to S. pyogenes. Acute maxillary sinusitis. (3) Uncomplicated skin and skin structure infections due to S. aureus (including �-lactamase producing strains) and S. pyogenes.

Contraindications: Allergy to cephalosporins.

Special Concerns: Reduce dose in compromised renal function. Safety and efficacy have not been determined in infants less than 6 months of age.

Side Effects: See Cephalosporins.

Drug Interactions: Antacids, aluminum- or magnesium-containing / Absorption of cefdinir Probenecid / Plasma levels of cefdinir enhanced effect

How Supplied: Capsules: 300 mg; Oral Suspension: 125 mg/5mL

Dosage
?Capsules Community-acquired pneumonia, uncomplicated skin and skin structure infections.
Adults and adolescents age 13 and older: 300 mg q 12 hr for 10 days.
Acute exacerbations of chronic bronchitis, acute maxillary sinusitis, or pharyngitis/tonsillitis.
Adults and adolescents age 13 and older: 300 mg q 12 hr or 600 mg q 24 hr for 10 days (5-10 days for pharyngitis/tonsillitis). Alternatively, 300 mg b.i.d. for 5 days for acute exacerbations of chronic bronchitis.
?Oral Suspension Acute bacterial otitis media, acute maxillary sinusitis, pharyngitis/tonsillitis.
Children, 6 months through 12 years: 7 mg/kg q 12 hr or 14 mg/kg q 24 hr for 10 days (5 days for acute otitis media and 5-10 days for pharyngitis/tonsillitis).
Uncomplicated skin and skin structure infections.
Children, 6 months through 12 years: 7 mg/kg q 12 hr for 10 days.